Question 1

What is PMB-CT01?

Accepted Answer

PMB-CT01 is a Other.

Question 2

How often does PMB-CT01 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was PMB-CT01 first tracked by Ergen?

Accepted Answer

First tracked on May 28, 2026.

Question 4

When was PMB-CT01 last mentioned in news?

Accepted Answer

Last active on May 28, 2026.

Question 5

What is PMB-CT01's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is PMB-CT01 in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving PMB-CT01?

Accepted Answer

PeproMene Bio PMB-CT01 Lymphoma Results (May 28, 2026, 6 articles).

Question 8

How did the "PeproMene Bio PMB-CT01 Lymphoma Results" event impact PMB-CT01?

Accepted Answer

PMB-CT01 is the investigational CAR T-cell therapy showing promising safety and durable responses in B-cell lymphomas, making it a key asset for PeproMene Bio and a potential new treatment option for patients.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.